Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol

Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol

To determine the efficacy of the treat and extend (TAE) protocol with intravitreal bevacizumab (IVB) for managing diabetic macular edema (DME).Retrospective, single-center study.For this retrospective study, 42 eyes of 42 patients were initially treated with 3 consecutive monthly IVB injections (loa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicine (Baltimore) 2017-04, Vol.96 (16), p.e6406-e6406
Hauptverfasser: Sugimoto, Masahiko, Ichio, Atsushi, Nunome, Takayasu, Kondo, Mineo
Format: Artikel
Sprache:eng
Schlagworte:
Angiogenesis Inhibitors - administration & dosage
Bevacizumab - administration & dosage
Diabetic Retinopathy - diagnostic imaging
Diabetic Retinopathy - drug therapy
Female
Follow-Up Studies
Humans
Intravitreal Injections
Macular Edema - diagnostic imaging
Macular Edema - drug therapy
Male
Middle Aged
Observational Study
Organ Size
Prospective Studies
Retrospective Studies
Tomography, Optical Coherence
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To determine the efficacy of the treat and extend (TAE) protocol with intravitreal bevacizumab (IVB) for managing diabetic macular edema (DME).Retrospective, single-center study.For this retrospective study, 42 eyes of 42 patients were initially treated with 3 consecutive monthly IVB injections (loading phase), after which they were selected for different additional therapies. For the TAE protocol, the baseline treatment interval was selected to be 8 weeks and was sequentially lengthened by 2 weeks if the central macular thickness (CMT) was
ISSN:0025-7974
1536-5964
DOI:10.1097/md.0000000000006406